Published in

Wiley, Macromolecular Rapid Communications, 19(33), p. 1613-1631, 2012

DOI: 10.1002/marc.201200354

Links

Tools

Export citation

Search in Google Scholar

Poly(2-oxazoline)s as Polymer Therapeutics

Journal article published in 2012 by Robert Luxenhofer ORCID, Yingchao Han, Anita Schulz, Jing Tong, Zhijian He, Alexander V. Kabanov, Rainer Jordan ORCID
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Poly(2-oxazoline)s (POx) are currently discussed as an upcoming polymer platform for biomaterials design and especially for polymer therapeutics. POx meet specific requirements needed for the development of next-generation polymer therapeutics such as biocompatibility, high modulation of solubility, variation of size, architecture as well as chemical functionality. Although in the early 1990s first and promising POx-based systems were presented, the field lay dormant for almost two decades. Only very recently, POx-based polymer therapeutics came back into the focus of very intensive research. In this review, we give an overview on the chemistry and physicochemical properties of POx and summarize the research of POx-protein conjugates, POx-drug conjugates, POx-based polyplexes and POx micelles for drug delivery.